The Low-Dose Peptide I Take

Why It Matters

Understanding weight‑independent effects of GLP‑1/GIP drugs could expand treatment options for cardiovascular, renal and joint disease, prompting clinicians to reconsider off‑label use and regulatory evaluation.

Key Takeaways

• GLP‑1 drugs provide cardiovascular benefits beyond weight loss
• Semaglutide improves kidney outcomes independent of weight reduction
• GLP‑1 agonists protect cartilage, enhancing osteoarthritis outcomes significantly
• Combination GLP‑1/GIP tirzepatide shows broader cardiovascular risk reduction
• Low‑dose tirzepatide reduces cravings, blood pressure, with manageable side effects

Summary

The video follows a 34‑year‑old general practitioner who injects 1.25 mg of tirzepatide weekly despite lacking diabetes or obesity, using the drug to tap into emerging evidence that GLP‑1 and GIP agonists confer health benefits beyond weight loss.

Recent large‑scale trials—SELECT, FLOW, and STEP‑9—show semaglutide cuts major cardiovascular events by 20 % in non‑diabetic patients, reduces kidney‑failure composites by 24 % independent of weight loss, and alleviates osteoarthritis pain. Parallel mouse studies demonstrated cartilage preservation that could not be explained by weight reduction alone.

In the SELECT trial 17,000 overweight adults saw cardiovascular risk fall even when weight loss was minimal. The FLOW trial reported similar kidney benefits. A Shenzhen team gave semaglutide to mice with osteoarthritis and matched‑weight‑loss controls; only the drug‑treated group retained cartilage. A pilot MRI study in 20 humans showed a 17 % increase in knee cartilage thickness after 24 weeks of tirzepatide plus hyaluronic acid.

These findings suggest GLP‑1/GIP agonists may act on receptors in heart, kidney and cartilage cells, offering therapeutic avenues for lean, non‑diabetic individuals. While the physician’s self‑experiment highlights potential personal benefits—reduced cravings, lower blood pressure, and minimal side effects—it also underscores the need for controlled trials before broader off‑label adoption.

Original Description

🩺 Get your personalized health plan: https://drstanfield.com

💊 Supplements I Take: https://drstanfield.com/pages/my-supplements

💊MicroVitamin+ (Pro) Powder: https://drstanfield.com/products/microvitamin-plus

💊MicroVitamin Standard Capsules: https://drstanfield.com/products/microvitamin

Timestamps:

00:00 Discovery of GLP-1 and Weight Loss Effects

01:33 Cardiovascular and Kidney Benefits of GLP-1

02:45 GLP-1 Medications and Cancer Progression

02:51 GLP-1 Medications and Joint Health

06:39 Benefits of GLP-1 and GIP Combination

08:57 Why Tirzepatide Over Retatrutide

09:52 My Personal Experience with Tirzepatide

10:23 Safety Concerns

✔️ X: https://x.com/BradStanfieldMD

✔️ Patreon: https://www.patreon.com/bradstanfieldmd

Here are the links to the research papers referenced in the video:

SELECT (Lincoff 2023) — https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

FLOW (Perkovic 2024) — https://www.nejm.org/doi/10.1056/NEJMoa2403347

SURPASS-CVOT primary (Nicholls 2025) — https://www.nejm.org/doi/abs/10.1056/NEJMoa2505928

Exenatide history (Wikipedia) — https://en.wikipedia.org/wiki/Exenatide

SCALE (Pi-Sunyer 2015) — https://www.nejm.org/doi/full/10.1056/NEJMoa1411892

STEP 1 (Wilding 2021) — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

ASCO 2026 — GLP-1 + cancer progression — https://www.oncology-central.com/asco-2026-glp-1s-could-reduce-the-risk-of-some-obesity-related-cancers-progressing/

Cartilage regeneration review — https://pmc.ncbi.nlm.nih.gov/articles/PMC10071204/

Weight loss → knee-joint load (Messier 2005) — https://pubmed.ncbi.nlm.nih.gov/15986358/

STEP 9 (semaglutide + knee OA) — https://www.nejm.org/doi/abs/10.1056/NEJMoa2403664

Chen pair-fed mice / semaglutide + OA (Cell Metabolism 2026) — https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00008-2

Di Chen quote — CGTN — https://news.cgtn.com/news/2026-02-12/-Weight-loss-wonder-drug-can-also-treats-osteoarthritis-study-finds-1KHcUiXzHsQ/p.html

ESSENCE (Sanyal 2025, MASH) — https://www.nejm.org/doi/full/10.1056/NEJMoa2413258

Klausen Lancet (semaglutide + AUD, 2026) — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3

Retatrutide Phase 2 (Jastreboff 2023) — https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Tirzepatide vs Semaglutide HR — https://www.nejm.org/doi/full/10.1056/NEJMoa2107519

Pancreatitis meta-analysis — https://pubmed.ncbi.nlm.nih.gov/32720500/

Thyroid cancer + semaglutide review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/

FDA suicide signal evaluation (Jan 2024) — https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

GLP-1 calorie-intake reduction — https://pmc.ncbi.nlm.nih.gov/articles/PMC11340591/

Mozaffarian 2025 Joint Advisory (multivitamin-mineral recommendation) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12304835/

MicroVitamin Labdoor review (99.7%) — https://labdoor.com/review/dr-brad-stanfield-microvitamin

Thumbnail by James Kelly

Video edited by Troy Young

Script by John Milliken

The links above are affiliate links, so I receive a small commission every time you use them to purchase a product. The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel.